ginsenoside-m1 and Psoriasis

ginsenoside-m1 has been researched along with Psoriasis* in 2 studies

Other Studies

2 other study(ies) available for ginsenoside-m1 and Psoriasis

ArticleYear
Ginsenoside compound K ameliorates imiquimod-induced psoriasis-like dermatitis through inhibiting REG3A/RegIIIγ expression in keratinocytes.
    Biochemical and biophysical research communications, 2019, 08-06, Volume: 515, Issue:4

    Psoriasis is a chronic inflammatory skin disease characterized by keratinocyte hyperproliferation. Ginsenoside compound K (CK), a bioactive metabolite of ginseng, modulates various skin disorders with an impact on keratinocyte biology. However, the effect of Ginsenoside CK in psoriasis has not been explored.. Our aim was to investigate whether ginsenoside CK could affect the homeostasis of keratinocytes and their expression of psoriasis-associated antimicrobial protein regenerating islet-derived protein 3-alpha (REG3A) and its murine ortholog RegIIIγ. We further explored the therapeutic potential of ginsenoside CK in imiquimod (IMQ)-induced psoriasis-like dermatitis.. The effects of ginsenoside CK in cell growth and apoptosis of human keratinocytes were measured by MTT assay and flow cytometry, respectively. Bax levels were evaluated by Western blot in HaCaT cells following ginsenoside CK stimulation. REG3A levels were assessed by RT-PCR and Western blot in human keratinocytes following interleukin (IL)-36γ and ginsenoside CK co-simulation. Utilizing IMQ-induced psoriasis mouse model, the therapeutic effects of 0.1% and 1% ginsenoside CK cream were assessed by skin thicknesses and histological examinations, and RegIIIγ level in the lesional skin was detected by Western blot and immunofluorescence.. Ginsenoside CK prohibited human keratinocyte proliferation but did not affect their apoptosis. Moreover, it inhibited IL-36γ-induced REG3A expression in HaCaT cells. Ginsenoside CK alleviated imiquimod-induced psoriasis-like hyperkeratosis and reduced RegIIIγ expression in the keratinocytes from lesional skin.. Ginsenoside CK ameliorated IMQ-induced psoriasis-like dermatitis possibly through inhibiting REG3A/RegIIIγ expression in keratinocytes, which highlighted a therapeutic potential of ginsenoside CK in psoriasis.

    Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dermatitis; Female; Ginsenosides; Humans; Imiquimod; Interleukin-1; Keratinocytes; Mice; Mice, Inbred C57BL; Pancreatitis-Associated Proteins; Psoriasis; Skin

2019
Effect of ginsenoside Rb1 and compound K in chronic oxazolone-induced mouse dermatitis.
    International immunopharmacology, 2005, Volume: 5, Issue:7-8

    During the screening program to discover antipsoriatic agents from natural products, ginseng was found to show inhibitory activity in oxazolone-induced mouse ear dermatitis. Therefore, the effects of a main constituent ginsenoside Rb1 isolated from ginseng and its metabolite compound K on oxazolone-induced mouse ear dermatitis were investigated. Compound K at concentrations of 0.02% and 0.05% also potently suppressed mouse ear swelling by 54% and 76% at 16 days, respectively, although ginsenoside Rb1 did not significantly show the inhibitory activity. The compound K also significantly reduced the levels of mRNA of cyclooxygenase (COX)-2, IL-1beta, TNF-alpha, IFN-gamma and IL-4 increased in oxazolone-applied mouse ears. Based on these findings, the compound K may improve contact dermatitis or psoriasis by the regulation of COX-2 produced by macrophage cells and interferon-gamma and IL-4 induced by Th cells.

    Topics: Animals; Cell Line; Chronic Disease; Cyclooxygenase 1; Cyclooxygenase 2; Dermatitis, Contact; Dinoprostone; Female; Ginsenosides; Macrophages; Membrane Proteins; Mice; Mice, Inbred ICR; Nitric Oxide; Oxazolone; Prostaglandin-Endoperoxide Synthases; Psoriasis; RNA, Messenger

2005